岸迈生物,一家专注于双特异性抗体技术的创新型国际化生物技术企业,今日正式向港交所递交招股书。公司依托自主知识产权的FIT-Ig®技术平台,开创性地将两个单抗序列融合,形成独特的双特异性抗体结构。该技术无需氨基酸突变或额外连接肽链,具备高成药性和产业化效率。目前,岸迈生物正基于此平台开发针对肿瘤免疫等高需求领域的原创产品,并通过全球技术授权与合作开发,加速平台战略拓展和产品多元化布局。这一进展标志着...
Source Link岸迈生物,一家专注于双特异性抗体技术的创新型国际化生物技术企业,今日正式向港交所递交招股书。公司依托自主知识产权的FIT-Ig®技术平台,开创性地将两个单抗序列融合,形成独特的双特异性抗体结构。该技术无需氨基酸突变或额外连接肽链,具备高成药性和产业化效率。目前,岸迈生物正基于此平台开发针对肿瘤免疫等高需求领域的原创产品,并通过全球技术授权与合作开发,加速平台战略拓展和产品多元化布局。这一进展标志着...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.